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Abstract
Background: Platelet-rich fibrin (PRF), a platelet-rich plasma (PRP) derivative mainly composed of fibrin networks,
has been increasingly demonstrated to be effective in wound healing in clinical and pre-clinical animal studies.
However, there has still been a concern that major growth factors may significantly be loss from PRF during its
preparation through the slow clotting process. To address this concern, we compared the angiogenic potential of
PRF and PRP by standardization of procedures based on volume ratios.
Methods: PRP, PRF, and platelet-poor plasma (PPP) were prepared from the peripheral blood of healthy donors.
PRF preparations were squeezed or homogenized to produce exudate (PRFexu) or extract (PRFext), respectively.
Concentrations of the angiogenic factors and their bioactivities were determined using ELISA kits, a scratch assay
using endothelial cells and a chicken chorioallantoic membrane (CAM) assay.
Results: In PRP and PRF preparations, both VEGF and PDGF-BB were significantly more concentrated than PPP. In
the scratch assay, PRFexu and PRFext were the most effective for wound closure. In the CAM assay, PRF membranes
were the most effective for neovascularization.
Conclusions: It is suggested that PRF preparations efficiently preserve the angiogenic factors and function not only
as a scaffolding material but as a reservoir of angiogenic factors in wound healing.
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Background
Since Marx’s publications [1, 2], platelet-rich plasma (PRP)
has been widely applied in regenerative therapy. However,
because the preparation protocol is relatively complex and
not standardized between laboratories, its clinical out-
comes have often varied significantly among individual
clinical research groups [3]. To overcome this disadvan-
tage, Choukroun and his co-workers developed platelet-
rich fibrin (PRF) by modifying the process of PRP
preparation [3–5]. PRF can be prepared solely through the
activation of an endogenous coagulation process without
the aid of animal-derived coagulants such as bovine throm-
bin. Its advantages include operator-friendly preparation
procedures and doctor-friendly handling when used in a
clinical setting. However, the primary and more important
advantage of PRF should be attributed to its clinical effect-
iveness rather than efficiency in preparation and handling.
Because PRF is mainly composed of fibrin fibers, it has
been generally thought that PRF preparations must be
distinguished from PRP, a “cocktail” of growth factors.
Furthermore, there has been a concern that most growth
factors may diffuse and be loss during the PRF prepar-
ation process. To address this concern, clinical and pre-
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clinical animal studies have increasingly been performed
over the past 2 years [6–16]. The majority of published
articles to date have concluded that PRF preparations
were more effective or equally effective to PRP prepara-
tions in wound healing and tissue regeneration. These
findings are not surprising because fibrin fibers would
be expected to function as an efficient carrier to form a
delivery system of growth factors [17]; however, the
methods for PRF preparation and application are often
not fully disclosed or vary across individual studies.
Therefore, for a more precise comparison, it is necessary
to standardize the procedures for preparation of PRF
and to normalize their effectiveness by utilizing known
volumes of blood samples.
For example, to standardize the handling of PRF exudate
(PRFexu), in a previous study [18], we developed a com-
pression device and proposed the use of this device to
create a PRF membrane with uniform thickness and to
minimize loss of PRFexu assuming that PRFexu contains
significant amounts of important growth factors for
wound healing. As a result of this comparative study using
an ex vivo chick embryo chorioallantoic membrane
(CAM) assay, it turned out that growth factors were dis-
tributed both in the exudate portion and in the fibrin
network. Therefore, to more precisely compare the PRF
with PRP preparations at the cellular and molecular levels,
it is necessary to standardize the preparation procedures
and to evaluate their potency by the volume ratios of the
originally collected peripheral blood samples with the
resulting preparation samples.
In this study, because the primary site of PRP action in
wound healing and tissue regeneration is the formation of
blood vessels [17, 19], we focused on vascular endothelial
growth factor (VEGF) and its target action of angiogenesis
and compared the concentrations of PRP and PRF prep-
arations as to their biological effectiveness using ELISA
and bioassay systems after performing the appropriate
normalization.
Methods
Preparation and clotting of PRP
As previously described [20, 21], blood was collected from
three healthy and non-smoking volunteers aged 28, 30,
and 54 years (two females; one male), and PRP was pre-
pared along with platelet-poor plasma (PPP) using the
two-step centrifugation protocol. The number of platelets
in the freshly prepared PRP and PPP samples was deter-
mined using an automated hematology analyzer (pocH
100iV diff: Sysmex, Kobe, Japan). Then, PRP and PPP
preparations were frozen and stored at −20 °C until fur-
ther used (usually within 2 weeks).
Preparation of PPP and PRP samples is shown in Fig. 1a.
For clotting, bovine thrombin (180 U) (Haematologic
Technologies, Inc., Essex Junction, VT, USA) and 10 %
CaCl2 (30 μL) were added to the indicated volumes of
PRP or PPP preparations to form 5 × 5 × 1 mm (width ×
length × thickness) membranes. The relative volumes of
individual preparations against the original blood samples
were calculated and are summarized in Table 1.
The study design and consent forms for all proce-
dures performed with the study subjects were
approved by the ethical committee for human subject
use at Niigata University Medical and Dental Hospital
in accordance with the Helsinki Declaration of 1975
and as revised in 2008.
Preparation, compression, and homogenization of PRF
As described previously [18], blood was collected from the
same donors and immediately centrifuged by a Medifuge
centrifugation system (Silfradent S. r. l., Santa Sofia, Italy).
Preparation of PRF samples, PRFexu and PRFext are
shown in Fig. 1b. After eliminating the red thrombus, the
Fig. 1 a Preparation of PPP and PRP samples. b Preparations of PRF samples (PRFexu and PRFext)
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resulting PRF preparations were compressed by the PRF
compression device [18]. As described earlier, the stainless
steel PRF compression device developed for PRF membrane
preparation was composed of two spoon shaped parts. The
clearance between the spoon parts when compressed was
adjusted to be 1 mm. Thus, when the PRF clots were com-
pressed with this device, a standard 1-mm thick PRF
membrane was consistently prepared.
After compression, PRF membranes were centrifuged to
squeeze out the PRFexu. Alternatively, PRF membranes
were minced and homogenized on ice for 1 min with a
micro-Multimixer (Ieda Trading, Corp., Tokyo, Japan) and
centrifuged to obtain supernatants (PRFext) (Fig. 1b). The
resulting PRFexu and PRFext were directly used along
with PRP and PPP preparations for ELISA and the
bioassays. Comparison of sample and preparation volumes
is shown in Table 1. PPP, PRP, and PRF membrane prepa-
rations were standardized by preparing them from the
same volume (10 mL) of blood samples.
Determination of growth factor levels by ELISA
The concentrations of VEGF, PDGF-BB, and soluble DLL1
in frozen PPP, PRP, and PRF samples were determined
using human VEGF, PDGF-BB, and DLL1 Quantikine
ELISA Kits (R&D Systems, Inc., Minneapolis, MN, USA).
Cell culture and scratch assay
Human umbilical vein endothelial cells (HUVECs) were
obtained from Cell Applications, Inc., (San Diego, CA,
USA) and cultured with HuMedia-EB2 supplemented
with growth factors (Kurabo, Tokyo, Japan). For the
scratch assay, the cells were seeded into 6-well plates at
a density of 1 × 105 cells/well and cultured in a CO2
incubator until they reached early confluence. The
medium was then replaced with HuMedia-EB2 supple-
mented with reduced amounts of growth factors (1:5 in
dilution). The monolayer was scratched using a scraper
with a 1-mm blade and incubated for an additional 24 h
with 2 % (v/v) PRFexu, PRFext, PRP, or PPP. The wound
areas were photographed at specific time points, and the
width of the scratched gap was determined using ImageJ
(National Institutes of Health, Bethesda, MD, USA).
Western blotting analysis
HUVECs were seeded onto 6-well plates at a density of
1 × 104 cells/well and pre-cultured for 2 days to form
subconfluent cultures. After washing, the cells were
treated with PPP, PRP, or PRFext in a CO2 incubator
(5 % CO2) for 10 min in serum-free Hank’s balanced
saline solution (HBSS). After washing twice with ice cold
PBS, the cells were lysed with Laemmli sample buffer as
previously described [22]. Protein samples were fraction-
ated using 10 % SDS-PAGE (ATTO, Tokyo, Japan) and
electro-blotted onto PVDF membranes using the
Trans-Blot® Turbo™ Transfer System (Bio-Rad Laboratories,
Hercules, CA, USA).
After blocking with diluted Block A (1:2) (DS Pharma,
Osaka, Japan) or 5 % BSA (Fraction V) (Sigma, St. Louis,
MO, USA) in 0.1 % Tween 20-containing TBS (T-TBS)
for 4–5 h at 4 °C, the membranes were probed overnight
at 4 °C with the following primary antibodies: rabbit
polyclonal anti-phospho-VEGFR2 (Y996) (1:2000 in dilu-
tion) (Cell Signaling Technology, Danvers, MA, USA),
rabbit polyclonal anti-VEGFR2 (D5B1) (1:2,000) (Cell
Signaling Technology), or goat polyclonal anti-actin anti-
body (1:1,000) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). After washing three times with T-TBS,
the membranes were probed with horseradish peroxidase-
conjugated goat polyclonal anti-rabbit IgG H&L (1:5,000)
(Abcam, Cambridge, MA, USA) or horseradish peroxidase-
conjugated donkey anti-goat IgG (Santa Cruz Biotech-
nology) for 45 min at 4 °C. After washing, images were
visualized using Clarity™ Western ECL Substrate (Bio-
Rad) and imaged using a cooled CCD camera system
(Image Capture; ATTO, Tokyo, Japan).















Starting blood sample volume (mL) 10a 10a 10a 10a 10 10 10
Resulting sample volume (mL)
(vs. starting volume)
2.5 (1:4) 1 (1:10) 1 (1:10) 1 (1:10) 1b (1:10)
Relative condensation (fold) 1 2.5 2.5 2.5
Volume needed to mold a clot (mL)
(vs. resulting sample volume)
0.25 (1:10) 0.2 (1:5)
Number of 5 × 5 × 1-mm membrane 10c 5c 5–7d
Relative condensation (fold) 1 2 1.4–2.0
aThis sample volume does not include the volume of acid citrate dextrose solution (ACD; 1.5 mL)
b(Acquired sample volume) = (blood sample volume) − (RBC fraction) − (serum volume)
cEstimated number of membranes
dAcquired number of membranes
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The ex vivo chorioallantoic membrane model
As described previously [18], fertilized chicken eggs were
incubated in a hatching incubator equipped with an
automatic rotator (KingSURO20; Belbird, Siki, Japan) at
37 °C with a relative air humidity of 65 %. On embryo
developmental day 11, a hole approximately 16 mm in
diameter was opened in the eggshell, and clots of PPP
and PRP and PRF membranes (5 × 5 mm) were placed
on the central area of the CAMs. After the holes were
sealed, the eggs were incubated for an additional 3 days.
The CAM vasculature was macroscopically photographed
at the initial time point (day 0) and the end point (day 3).
The number of vessels in the center circle (1 cm2) was
determined using image analysis software (WinROOF,
Mitani Corp., Fukui, Japan). In brief, RGB (red-green-
blue) channel layers were separated, and the blue chan-
nel layer was manually adjusted to its threshold. After
the images were binarized to clearly show blood vessels
[23], the number of vessels was counted manually per cm2.
Histological and immunohistochemical examination of CAM
After counting the number of blood vessels, CAMs were
harvested, fixed, and embedded in paraffin for histological
examination. As described previously [24], deparaffinized
sections were subjected to hematoxylin-eosin (HE)
staining and Masson’s trichrome staining.
Alternatively, the sections were antigen-retrieved and
blocked with 2.5 % normal horse serum (Vector Labs,
Burlingame, CA) and subsequently probed with a mouse
monoclonal anti-α-smooth muscle actin (α-SMA) anti-
body (1:100) (Abcam, Cambridge, MA, USA) overnight
at 4 °C, followed by incubation in the ImmPRESS® anti-
mouse IgG (Vector). Immunoreactive proteins were
visualized by a DAB substrate solution (Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD).
The number of α-SMA+ vessel-like structure (shown
by arrows) inside the CAM was determined using image
analysis software (WinROOF, Mitani Corp., Fukui,
Japan). In brief, after the contrast of the images was
enhanced manually, the number of vessels was counted.
The area of the CAM in the cross-sections was also
evaluated. Then, the number of vessels was normalized
Fig. 2 The concentration of platelets, VEGF, PDGF-BB, and DLL1 in PPP, PRP, PRFexu, and PRFext preparations. n = 5
Fig. 3 The time-course effects of PPP, PRP, PRFexu, or PRFext
preparations on the wound prepared in HUVEC cultures. The
controls included no plasma-derived supplements. n = 5
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by utilizing the ratio of the area to the number of vessels
per unit square (mm2).
Immunofluorescence examination
HUVECs were seeded onto glass coverslips and pre-
cultured for 24 h to form subconfluent cultures. The
cells were treated with 2 % PRP or PRFext for up to 3 h.
The cells were then fixed and treated with FITC-
conjugated mouse monoclonal anti-CD41 (1:5) (Beckman
Coulter, Inc., Brea, CA, USA) or FITC-conjugated rabbit
polyclonal anti-human fibrinogen (1:20) (Medical &
Biological Laboratories Co., Ltd, Nagoya, Japan) for
1 h at 4 °C, as described previously [25]. After three
washes with T-PBS, the cells were mounted with
VECTASHIELD Mounting Medium with DAPI (Vector
Laboratories, Burlingame, CA, USA) and examined using
a fluorescence microscope (Nikon, Tokyo, Japan).
Statistical analysis
The data were reported as the mean value ± standard
deviation (S.D.). For multi-group comparisons, statistical
analyses were performed to compare the mean values
Fig. 4 Immunofluorescence examination of fibrin fiber formation (a) and CD41+ platelet distribution (b) in PRP-treated HUVEC cultures. HUVECs
were treated with 2 % PRFext- or 2 % PRP-containing media for up to 3 h. The cells were fixed and subjected to immunofluorescence examination.
Similar data were obtained from two additional independent experiments (n = 3). Bar = 20 μm
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using one-way analysis of variance (ANOVA) followed
by Tukey’s multiple comparison test (SigmaPlot 12.5;
Systat Software, Inc., San Jose, CA, USA). P values <0.05
were considered significant.
Results
The concentration of platelets and growth factors in
PPP, PRP, and PRF preparations are shown in Fig. 2. In
PRP preparations, platelets were concentrated approxi-
mately 6.8-fold over PPP preparations. Although it is
challenging to accurately count platelets in PRF prepara-
tions, we previously observed by SEM examination that
platelets aggregated and attached to the surface of the
PRF membrane, suggesting that platelets were concen-
trated on PRF membrane surfaces [18]. In support of
this finding, PDGF-BB, a platelet-specific growth factor,
was concentrated 7.6 and 6.5-fold in PRP and PRFext
preparations, respectively, when compared with PPP
preparations. The potent angiogenic factors, VEGF and
soluble DLL1, demonstrated contrasting results. VEGF
was concentrated in PRP and PRFext preparations 6.5
and 10.0-fold, respectively, when compared with PPP
preparations, whereas soluble DLL1 was not concen-
trated in either PRP or PRFext when compared with
PPP. In addition, the concentration of another angio-
genic factor, bFGF, was too low to reproducibly be
detected in any of the preparations tested in this study
(data not shown).
The time-course effects of PPP, PRP, and PRF prepara-
tions on simulated wounds prepared in HUVEC confluent
cultures are shown in Fig. 3. The wound closure was facili-
tated by PRP (2 %) and PRF preparations (2 %), but not
PPP preparations (2 %). The order of potency was
PRFexu ≥ PRFext > PRP > > PPP at 7 h of incubation. The
statistical significances are P < 0.05 (PPP vs. PRFexu; PPP
vs. PRFext; control vs. PPP) and P < 0.001 (control vs.
PRFext; control vs. PRFexu). The controls included no
plasma-derived supplements.
The time-course effects of PRFext and PRP on the for-
mation of fibrin fibers in HUVEC cultures are shown in
Fig. 4a. Typical fibrin fibers were formed time depend-
ently only in PRP-added cultures, but not in controls
without plasma-derived supplements or in PRF-added
cultures. The distributions of CD41+ platelets in PRP-
treated HUVEC cultures are shown in Fig. 4b. Significant
numbers of CD41+ particles were found in PRP-added
cultures, but not in the control cultures without plasma-
derived supplements. A low number of CD41+ particles
were found in PRF-added cultures.
The dose-dependent effects of PRP and PRFext prepa-
rations on the phosphorylation of VEGFR2 are shown in
Fig. 5. PRP and PRF preparations (0.25–2 %) dose-
dependently phosphorylated VEGFR2 when compared
with pan VEGFR2, and the potency of PRFext prepara-
tions were similar to that of PRP preparations.
The effects of clotted PPP, clotted PRP, and PRF mem-
brane preparations on new blood capillary formation in
the CAM assay are shown in Fig. 6. New capillary for-
mation at 3 days after application was macroscopically
examined. The image analysis for quantitation demon-
strated that both PRP and PRF preparations significantly
increased the number of blood capillaries. The order of
potency was PRF ≥ PRP ≥ PPP and the statistical signifi-
cances are P < 0.05 (control vs. PPP), P < 0.01 (PPP vs.
PRF), and P < 0.001 (control vs. PRP; control vs. PRF).
The controls included no plasma-derived supplements.
These effects were further confirmed by determin-
ing the number of mature blood vessels based on the
concept that α-SMA is a marker of vascular smooth
muscle cells. Alpha-SMA was immunohistochemically
evaluated to determine the number of blood vessels.
Immunohistochemical examination of the effects of
clotted PPP, clotted PRP, and PRF membrane prepa-
rations on formation of α-SMA+ mature blood
vessels in the CAM. As earlier demonstrated in the
macroscopic examination of new capillary formation
(Fig. 6), both PRP and PRF preparations significantly
increased the number of mature blood vessels (Fig. 7).
Here again, a similar trend of α-SMA-staining po-
tency for estimating the number of mature blood
vessels was PRF ≥ PRP > PPP. The statistical signifi-
cances were P < 0.05 (control vs. PRP) and P < 0.01
Fig. 5 The dose-dependent effects of PRP (a) and PRFext preparations
(b) on phosphorylation of VEGFR2 in HUVEC at 10 min. Similar data
were obtained from three additional independent experiments (n = 4)
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(control vs. PRF; PPP vs. PRF). The controls included
no plasma-derived supplements.
Further histological examination with Masson’s tri-
chrome staining was performed to examine the changes
taking place in the CAM assay. The effects of clotted
PPP, clotted PRP, and PRF membrane preparations on
the thickness and the structure of the CAM are shown
in Fig. 8. These preparations all significantly thickened
the CAM by stimulating fibroblast proliferation and
extracellular matrix (ECM) deposition. However, both
PRP and PRF preparations were more potent at stimu-
lating fibroblast proliferation and collagen deposition
Fig. 6 The effects of clotted PPP, clotted PRP, and PRF membrane preparations on new blood vessel formation in the CAM assay. The controls
included no plasma-derived supplements. n = 5
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than PPP preparations. The controls included no
plasma-derived supplements.
Discussion
The PRF preparation procedure presented here is simple
and less technique-sensitive than previously reported;
however, it cannot be ruled out that, because of slow
clotting, the centrifugation process possibly activates
platelets to release growth factors more than what was
predicted. It has widely been thought; however, without
clear evidence, that even though they function as a scaf-
folding material, PRF preparations may not provide
growth factors to the level that will synergistically facili-
tate wound healing and tissue regeneration. Dohan
Ehrenfest and co-workers first reported that PRF
preparations contain significant amounts of growth fac-
tors [5], and we independently demonstrated that the
growth factors are distributed not only in PRFexu but
also on and among fibrin fibers [18] (Kawase et al., un-
published observations). Therefore, evidence supports
the notion that PRF preparations contain and deliver
growth factors to the site of wound-healing.
Furthermore, it has recently been demonstrated in
clinical and pre-clinical animal studies that PRF prepara-
tions have the potential of tissue regeneration at levels
almost identical to or even greater than PRP preparations
[6–16]. However, the majority of these results were ob-
tained from macroscopic and/or histological examinations
and therefore, these studies were phenomenological and
did not investigate the mechanism or the mode of PRF
Fig. 7 Immunohistochemical examination of the effects of clotted PPP, clotted PRP, and PRF membrane preparations on formation of α-SMA+
matured blood vessels in the CAM. Representative photomicrographs of α-SMA+ matured blood vessels (indicated by arrows). The controls
included no plasma-derived supplements. n = 5
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action. To our knowledge, the potency and efficacy of PRP
and PRF preparations have not precisely been compared
with each other at the cellular and molecular levels. One
of the possible reasons is that clinicians require evidence to
support their clinical use of PRF. From a more experimen-
tal point of view, the lack of appropriate standardization or
normalization methods between laboratories has hindered
the comparison of PRP with PRF in wound-healing investi-
gations. In this study, individual samples were normalized
based on the volume ratio of the original whole blood sam-
ples to the resulting products (Table 1). It may not be the
most suitable for quantitative comparison; however, we be-
lieve that the data we obtained will support or explain the
previously published data [26–28].
In our study, the ELISA results of the PDGF-BB and
VEGF, representative growth factors stored in platelets,
demonstrated that platelets were highly concentrated in
PRF preparations as well as in PRP preparations. In bio-
assays, PRF preparations exerted significant effects on
wound closure and neovascularization at levels some-
what greater than PRP preparations. We speculate that a
factor(s) existing in PRP, but not in PRF preparations,
may attenuate the effect of PRP. The most plausible
candidate is fibrinogen/fibrin because insoluble fibrin
functions not only as a scaffolding material for many cell
types but also as a carrier of growth factors [18, 29]. In
previous studies [30] (Kawase et al., unpublished obser-
vations), we observed that fibrin fibers were formed by
the addition of PRP preparations within 30 min and
grown thereafter in human periodontal ligament cell cul-
tures and osteoblastic MG63 cell cultures. In this study,
an immunofluorescence examination demonstrated that
fibrin fibers were similarly formed in HUVEC cultures
within 60 min of PRP application, but not PRFext
Fig. 8 Histological examination of the effects of clotted PPP, clotted PRP, and PRF membrane preparations on the thickness and the structure of
the CAM. Representative photomicrographs of Masson’s trichrome staining (n = 5). Cell nuclei and collagen are stained red and blue, respectively.
Asterisks represent the regions for evaluation of cell density and collagen deposition. The controls included no plasma-derived supplements
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application, and grown over time. Therefore, it is plaus-
ible that many growth factors can be trapped by the
newly formed fibrin fibers.
Furthermore, it was demonstrated that many CD41+
particles, i.e., platelets and/or their membrane debris,
were present in HUVEC cultures treated with PRP prep-
arations, but not PRFext preparations. It is known that
endothelial cells bind to platelets through integrin αvβ3
and CD40 [31]. Activation of integrin αvβ3 facilitates cell
migration [32], whereas activation of CD40 inhibits cell
migration [33]. In our case, activation of CD40 was
probably more dominant than the integrin to reduce
HUVEC migration.
When the two PRF preparation forms, i.e., PRFexu
and PRFext, were compared by ELISA, both PDGF-BB
and VEGF were contained at significantly higher levels
in PRFext than in PRFexu. However, the bioassay using
the HUVEC scratch assay demonstrated that the poten-
cies of the PRFext and PRFexu were almost identical. At
present, we do not have strong evidence to explain the
discrepancy between the concentrations evaluated by
ELISA and the order of potency obtained in the scratch
assay for PRFext and PRFexu. In conjunction with the
well-known fact that PRP preparations contain a variety
of growth factors [17], it seems likely that PDGF and
VEGF, even at lower concentrations in PRFexu may act
synergistically with other growth factors, such as TGFβ,
bFGF, EGF, and IGF-I, to exert the maximum effects on
cell migration.
In a previous study [25], we demonstrated using
Western blotting analysis that PRP stimulates VEGF
receptor type 2 (VEGFR2) to accelerate endothelial
cell motility and wound closure. In this study, we
demonstrated that PRFext acted on HUVEC and
phosphorylated VEGFR2 in a dose-dependent manner
that was almost identical to that of PRP. This finding
is essentially consistent with the data obtained from
the immunological determinations. In this study, we
did not demonstrate the direct activation of PDGF
receptors by PRF and PRP preparations. However,
judging from the literature previously published [34],
it is anticipated that PDGF and VEGF synergistically
function to facilitate neovascularization during the
wound healing process.
The CAM assay provided additional interesting as well
as informative data. The CAM was thickened by all
preparations, and both PRP and PRF preparations were
more potent than PPP preparations. This phenomenon
could be explained by the direct action of TGF-β and
PDGF, in addition to the probable indirect action of VEGF,
all of which are concentrated in both PRP and PRF prepa-
rations [17, 20, 35, 36] and capable of stimulating the
proliferation of fibroblasts. Among them, TGF-β is stored
in a latent form in the extracellular matrix [37] and
functions as the most potent known growth factor
involved in collagen production [38, 39]. According to a
recent review article [38], it was suggested that VEGF,
TGF-β, and PDGF provided by PRP or PRF preparations
in high concentrations cooperatively induced dynamic re-
ciprocal interactions between the cells and ECM to
thicken the CAM. In addition, it turns out that this simple
ex vivo experimental system can be applied in examining
possible dynamic interactions between ECM and CAM.
Conclusions
These findings suggest that the major angiogenic growth
factors, such as PDGF and VEGF, are not significantly
diffused away from platelets activated by endogenous
thrombin during centrifugation but efficiently preserved
in PRF preparations and that the angiogenic potential of
PRF preparations is compatible with that of PRP prepa-
rations. In conjunction with the user-friendly prepar-
ation procedure and high-handling efficiency, we would
recommend the clinical use of PRF preparations as a
higher-quality, clinically effective substitute for PRP
preparations in wound healing therapy.
Abbreviations
ACD: acid citrate dextrose solution; ANOVA: one-way analysis of variance;
CAM: chick embryo chorioallantoic membrane; DLL1: delta-like protein 1;
ECM: extracellular matrix; EGF: epidermal growth factor; ELISA: enzyme-linked
immunosorbent assay; HE: hematoxylin-eosin; HUVEC: human umbilical vein
endothelial cells; IGF-I: insulin-like growth factor-I; PDGF: platelet-derived
growth factor; PPP: platelet-poor plasma; PRF: platelet-rich fibrin;
PRFext: platelet-rich fibrin extract; PRFexu: platelet-rich fibrin exudate;
PRP: platelet-rich plasma; RGB: red-green-blue; TGFβ: transforming growth
factor-β; T-TBS: 0.1 % tween 20-containing Tris-based saline; VEGF: vascular
endothelial growth factor; VEGFR2: VEGF receptor type 2; α-SMA: α-smooth
muscle actin.
Competing interests
Author MK, TK, KO, HY, and LFW state that there are no conflicts of interest.
Authors’ contributions
MK and TK conceived and designed the study, performed the experiments,
and wrote the manuscript. KO performed the experiments and data analysis.
HY and LFW participated in manuscript preparation. All authors read and
approved the final version of the manuscript.
Acknowledgements
This project was funded through support by JSPS KAKENHI (Grant
#23592881, #24390443, and #24390465).
Author details
1Division of Oral Bioengineering, Institute of Medicine and Dentistry, Niigata
University, Niigata, Japan. 2Division of Periodontology, Institute of Medicine
and Dentistry, Niigata University, Niigata, Japan. 3Advanced Research Center,
The Nippon Dental University School of Life Dentistry at Niigata, Niigata,
Japan. 4Division of Periodontology, Department of Developmental and
Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis,
MN, USA.
Received: 26 August 2015 Accepted: 17 November 2015
Kobayashi et al. International Journal of Implant Dentistry  (2015) 1:31 Page 10 of 11
References
1. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR.
Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638–46.
2. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac
Surg. 2004;62:489–96.
3. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, et al.
Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V:
histologic evaluations of PRF effects on bone allograft maturation in sinus
lift. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:299–303.
4. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al.
Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I:
technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2006;101:e37–44.
5. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al.
Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II:
platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 2006;101:e45–50.
6. Gassling VL, Acil Y, Springer IN, Hubert N, Wiltfang J. Platelet-rich plasma
and platelet-rich fibrin in human cell culture. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2009;108:48–55.
7. Giannini S, Cielo A, Bonanome L, Rastelli C, Derla C, Corpaci F, et al.
Comparison between PRP, PRGF and PRF: lights and shadows in three
similar but different protocols. Eur Rev Med Pharmacol Sci. 2015;19:927–30.
8. Jeong KI, Kim SG, Oh JS, Lee SY, Cho YS, Yang SS, et al. Effect of platelet-rich
plasma and platelet-rich fibrin on peri-implant bone defects in dogs.
J Biomed Nanotechnol. 2013;9:535–7.
9. Kim TH, Kim SH, Sandor GK, Kim YD. Comparison of platelet-rich plasma
(PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) in
rabbit-skull defect healing. Arch Oral Biol. 2014;59:550–8.
10. Lichtenfels M, Colome L, Sebben AD, Braga-Silva J. Effect of platelet rich
plasma and platelet rich fibrin on sciatic nerve regeneration in a rat model.
Microsurgery. 2013;33:383–90.
11. Narang I, Mittal N, Mishra N. A comparative evaluation of the blood clot,
platelet-rich plasma, and platelet-rich fibrin in regeneration of necrotic
immature permanent teeth: a clinical study. Contemp Clin Dent. 2015;6:63–8.
12. Passaretti F, Tia M, D'Esposito V, De Pascale M, Del Corso M, Sepulveres R,
et al. Growth-promoting action and growth factor release by different
platelet derivatives. Platelets. 2014;25:252–6.
13. Hatakeyama I, Marukawa E, Takahashi Y, Omura K. Effects of platelet-poor
plasma, platelet-rich plasma, and platelet-rich fibrin on healing of extraction
sockets with buccal dehiscence in dogs. Tissue Eng Part A. 2014;20:874–82.
14. He L, Lin Y, Hu X, Zhang Y, Wu H. A comparative study of platelet-rich fibrin
(PRF) and platelet-rich plasma (PRP) on the effect of proliferation and
differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2009;108:707–13.
15. Pradeep AR, Rao NS, Agarwal E, Bajaj P, Kumari M, Naik SB. Comparative
evaluation of autologous platelet-rich fibrin and platelet-rich plasma in the
treatment of 3-wall intrabony defects in chronic periodontitis: a randomized
controlled clinical trial. J Periodontol. 2012;83:1499–507.
16. Bajaj P, Pradeep AR, Agarwal E, Rao NS, Naik SB, Priyanka N, et al.
Comparative evaluation of autologous platelet-rich fibrin and platelet-rich
plasma in the treatment of mandibular degree II furcation defects: a
randomized controlled clinical trial. J Periodontal Res. 2013;48:573–81.
17. Kawase T. Platelet-rich plasma and its derivatives as promising bioactive
materials for regenerative medicine: basic principles and concepts
underlying recent advances. Odontology. 2015;103:126–35.
18. Kobayashi M, Kawase T, Horimizu M, Okuda K, Wolff LF, Yoshie H. A
proposed protocol for the standardized preparation of PRF membranes for
clinical use. Biologicals. 2012;40:323–9.
19. Bir SC, Esaki J, Marui A, Yamahara K, Tsubota H, Ikeda T, et al.
Angiogenic properties of sustained release platelet-rich plasma:
characterization in-vitro and in the ischemic hind limb of the mouse.
J Vasc Surg. 2009;50:870–9. e2.
20. Okuda K, Kawase T, Momose M, Murata M, Saito Y, Suzuki H, et al. Platelet-
rich plasma contains high levels of platelet-derived growth factor and
transforming growth factor-beta and modulates the proliferation of
periodontally related cells in vitro. J Periodontol. 2003;74:849–57.
21. Nakajima Y, Kawase T, Kobayashi M, Okuda K, Wolff LF, Yoshie H. Bioactivity
of freeze-dried platelet-rich plasma in an adsorbed form on a
biodegradable polymer material. Platelets. 2012;23:594–603.
22. Uematsu K, Kawase T, Nagata M, Suzuki K, Okuda K, Yoshie H, et al. Tissue
culture of human alveolar periosteal sheets using a stem-cell culture medium
(MesenPRO-RS): in vitro expansion of CD146-positive cells and concomitant
upregulation of osteogenic potential in vivo. Stem Cell Res. 2013;10:1–19.
23. Nagata M, Hoshina H, Li M, Arasawa M, Uematsu K, Ogawa S, et al. A clinical
study of alveolar bone tissue engineering with cultured autogenous
periosteal cells: coordinated activation of bone formation and resorption.
Bone. 2012;50:1123–9.
24. Kawase T, Okuda K, Kogami H, Nakayama H, Nagata M, Nakata K, et al.
Characterization of human cultured periosteal sheets expressing bone-
forming potential: in vitro and in vivo animal studies. J Tissue Eng Regen
Med. 2009;3:218–29.
25. Kawase T, Tanaka T, Okuda K, Tsuchimochi M, Oda M, Hara T. Quantitative
single-cell motility analysis of platelet-rich plasma-treated endothelial cells
in vitro. Cytoskeleton (Hoboken). 2015;72:246–55.
26. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen
and fibrin and stimulates endothelial cell proliferation. Blood. 2000;96:3772–8.
27. Wong C, Inman E, Spaethe R, Helgerson S. Fibrin-based biomaterials to
deliver human growth factors. Thromb Haemost. 2003;89:573–82.
28. Kumar RV, Shubhashini N. Platelet rich fibrin: a new paradigm in periodontal
regeneration. Cell Tissue Bank. 2013;14:453–63.
29. Janmey PA, Winer JP, Weisel JW. Fibrin gels and their clinical and
bioengineering applications. J R Soc Interface. 2009;6:1–10.
30. Kawase T, Okuda K, Wolff LF, Yoshie H. Platelet-rich plasma-derived fibrin
clot formation stimulates collagen synthesis in periodontal ligament and
osteoblastic cells in vitro. J Periodontol. 2003;74:858–64.
31. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis.
Hematology Am Soc Hematol Educ Program. 2011;2011:51–61.
32. Gao B, Saba TM, Tsan MF. Role of alpha(v)beta(3)-integrin in TNF-alpha-
induced endothelial cell migration. Am J Physiol Cell Physiol. 2002;283:
C1196–205.
33. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand
inhibits endothelial cell migration by increasing production of endothelial
reactive oxygen species. Circulation. 2002;106:981–6.
34. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual
growth factor delivery. Nat Biotechnol. 2001;19:1029–34.
35. De Pascale MR, Sommese L, Casamassimi A, Napoli C. Platelet derivatives in
regenerative medicine: an update. Transfus Med Rev. 2015;29:52–61.
36. Amable P, Carias RB, Teixeira MV, da Cruz PI, Correa do Amaral RJ, Granjeiro
J, et al. Platelet-rich plasma preparation for regenerative medicine:
optimization and quantification of cytokines and growth factors. Stem Cell
Research Therapy. 2013;4:67.
37. Robertson IB, Horiguchi M, Zilberberg L, Dabovic B, Hadjiolova K, Rifkin DB.
Latent TGF-beta-binding proteins. Matrix Biol. 2015; DOI: 10.1016/j.matbio.
2015.05.005.
38. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth
factors in wound healing. Wound Repair Regen. 2009;17:153–62.
39. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors
and cytokines in wound healing. Wound Repair Regen. 2008;16:585–601.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Kobayashi et al. International Journal of Implant Dentistry  (2015) 1:31 Page 11 of 11
